LIPS-B: Lung Injury Prevention Study With Budesonide and Beta

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

July 31, 2015

Study Completion Date

December 31, 2015

Conditions
Acute Respiratory Distress Syndrome (ARDS)
Interventions
DRUG

Budesonide

Subjects will receive the standard aerosolized dose of budesonide (0.5 mg).

DRUG

Placebo

Aerosolized normal saline will be prepared to mimic the intervention arm, with the quantity, appearance and timing of the doses the being the same.

DRUG

Formoterol

Subjects will receive the standard aerosolized dose of formoterol (20 mcg) .

Trial Locations (5)

32224

Mayo Clinic in Florida, Jacksonville

55905

Mayo Clinic in Rochester, Rochester

85721

University of Arizona, Tucson

94305

Stanford University, Stanford

02215

Beth Israel Medical Center, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Stanford University

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

University of Arizona

OTHER

collaborator

National Center for Research Resources (NCRR)

NIH

lead

Mayo Clinic

OTHER